Fabtech Technologies Limited, a leading biopharma engineering company, made its stock market debut on Tuesday, October 7, 2025, following the completion of its initial public offering (IPO). Shares of Fabtech Technologies were listed at ₹192 apiece on the National Stock Exchange (NSE), marking a modest premium of ₹1 or 0.5% over the issue price of ₹191. On the Bombay Stock Exchange (BSE), the shares also opened at ₹192 per share. However, shortly after listing, the stock witnessed a decline of approximately 5%, touching an intraday low of ₹181.45 on BSE and ₹182.40 on NSE, reflecting early market volatility.
Subscription and IPO Details
The Fabtech Technologies IPO was priced in the range of ₹181 to ₹191 per share, comprising a fresh issue of 12.1 million equity shares, entirely consisting of new shares. There was no offer-for-sale (OFS) component in this IPO. Investors were able to bid in lots of 75 shares. The subscription window was open from September 29 to October 1, 2025, and the basis of allotment was finalised on October 3, 2025.
The offering saw strong participation from multiple investor segments. Overall subscription stood at 2.03 times, with retail investors leading at 2.08 times oversubscription, followed by Qualified Institutional Buyers (QIBs) at 2.03 times and Non-Institutional Investors (NIIs) at 1.97 times. This indicates steady investor interest despite the modest listing gains.
Use of IPO Proceeds
According to the Red Herring Prospectus (RHP), Fabtech Technologies intends to utilise the net proceeds from the IPO for a combination of business needs. Approximately ₹127 crore will be allocated to fund working capital requirements, while ₹30 crore is earmarked for inorganic growth through strategic acquisitions. The remaining funds are planned for general corporate purposes, supporting the company’s expansion and operational objectives.
Management and Advisors
Bigshare Services served as the registrar for the IPO, ensuring smooth allotment and share transfer processes, while Unistone Capital acted as the sole book-running lead manager, overseeing the successful execution of the offering.
About Fabtech Technologies
Incorporated as a biopharma engineering firm, Fabtech Technologies provides end-to-end engineering solutions, focusing on pharmaceutical manufacturing and process engineering. The company offers technology-driven solutions that support critical operations in drug development, production, and quality management. Fabtech serves a diverse client base across India, leveraging its expertise to enhance operational efficiency and drive innovation in the biopharma sector.
Also Read:
- Glottis IPO: Stock Opens Substantially Lower, Lists 32% Below Issue Price on BSE and 35% on NSE
- Pace Digitek IPO Listing: Shares Open with 3% Gain over Issue Price on Exchanges
- Jinkushal Industries IPO: Shares Make Modest Debut, List 3% above Issue Price
- TruAlt Bioenergy IPO: Shares List at 10% Premium over IPO price
Conclusion
The Fabtech Technologies IPO marks an important step for the company in accessing capital to fund growth and strategic initiatives. While the market debut was muted, listing just above the issue price and experiencing an early dip, the strong subscription across investor categories reflects investor confidence in the company’s long-term potential. With targeted utilisation of IPO proceeds and a focus on both organic and inorganic growth, Fabtech Technologies is well-positioned to expand its footprint in the biopharma engineering domain.
If you are exploring more investment opportunities, check out our dedicated page on upcoming IPO listings to stay updated on the latest market offerings.
